NIH-funded study identifies benefits, risks of treatments for nonviable pregnancy of unknown location

Aug. 4, 2021

Preemptive treatment for a nonviable pregnancy of unknown location—a situation in which there is a positive pregnancy test result but the location of the pregnancy cannot be confirmed within or outside the uterus with other diagnostic tests—resolves the condition more rapidly than treating symptoms as they arise, suggests a study supported by the National Institutes of Health.

However, both treatment approaches convey similar risks of adverse events, principally vaginal bleeding or, when the pregnancy is later determined to be an ectopic pregnancy (pregnancy outside of the uterus), rupture of a fallopian tube.

When a pregnancy is not progressing as expected and cannot be visualized with ultrasound and other physical examinations, pregnancy of unknown location is confirmed by detection of human chorionic gonadotropin (hCG), a hormone secreted by cells that later become the placenta. Treatment is typically offered when hCG levels remain consistently low, an indication that the fetus did not develop and only remnant cells remain.

If the pregnancy is later determined to be an ectopic pregnancy, if it is untreated, it may lead to severe bleeding and death of the mother. Similarly, a nonviable pregnancy elsewhere may lead to bleeding or scarring of the uterus, which could complicate future pregnancies.

The study was conducted by Kurt T. Barnhart, M.D., of the University of Pennsylvania and colleagues. It appears in the Journal of the American Medical Association.

“The findings suggest that treatment can be tailored to the wishes and needs of each individual patient,” said study author Esther Eisenberg, M.D., M.P.H., of the NICHD Fertility and Infertility Branch. The study authors added that participants in all the study groups rated the treatment they received as satisfactory and acceptable.

Little research has been conducted on the most effective treatment for pregnancy of unknown location. Treatment options include the drug methotrexate, evacuation (scraping) of the uterine lining, or expectant management — close observation of the patient and foregoing treatment unless symptoms occur.

The current study involved 253 patients. Researchers found that those given methotrexate, with or without uterine evacuation, recovered more quickly, without the need for additional treatment, compared to those in the expectant management group. Of the total, five patients had surgery for ectopic pregnancy: two in the expectant management group, two who underwent uterine evacuation, and one treated with methotrexate.

Patients were randomized to receive either expectant management, uterine evacuation followed by methotrexate, if needed, or two doses of methotrexate alone. Traditionally, uterine evacuation is performed to identify the location of the nonviable pregnancy. If placental cells are not found in the uterus, then the pregnancy is ectopic, and methotrexate may be given.

NIH study

Photo 79060266 © Susanne Neal |
Photo 37021977 © Anton Starikov |
37129089 © Tyler Olson, 26709588 © Dmitry Kalinovsky |
204557142 © Andrei Malov |